KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Operating Leases (2019 - 2026)

Esperion Therapeutics filings provide 7 years of Operating Leases readings, the most recent being $2.8 million for Q4 2025.

  • On a quarterly basis, Operating Leases fell 48.13% to $2.8 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.8 million, a 48.13% decrease, with the full-year FY2025 number at $2.8 million, down 48.13% from a year prior.
  • Operating Leases hit $2.8 million in Q4 2025 for Esperion Therapeutics, up from $767000.0 in the prior quarter.
  • In the past five years, Operating Leases ranged from a high of $5.3 million in Q4 2024 to a low of $47000.0 in Q3 2022.
  • Median Operating Leases over the past 5 years was $1.8 million (2021), compared with a mean of $1.9 million.
  • Biggest five-year swings in Operating Leases: crashed 96.42% in 2022 and later soared 4259.57% in 2023.
  • Esperion Therapeutics' Operating Leases stood at $524000.0 in 2021, then increased by 26.91% to $665000.0 in 2022, then skyrocketed by 354.14% to $3.0 million in 2023, then soared by 75.86% to $5.3 million in 2024, then tumbled by 48.13% to $2.8 million in 2025.
  • The last three reported values for Operating Leases were $2.8 million (Q4 2025), $767000.0 (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.